Compare WLDN & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDN | RNA |
|---|---|---|
| Founded | 1964 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 227.6M |
| IPO Year | 2006 | 2025 |
| Metric | WLDN | RNA |
|---|---|---|
| Price | $80.06 | $14.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 20 |
| Target Price | ★ $114.50 | $69.26 |
| AVG Volume (30 Days) | 248.6K | ★ 375.2K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.89 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $273,352,000.00 | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | $12.05 | $18.11 |
| P/E Ratio | $22.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.60 | $11.95 |
| 52 Week High | $137.00 | $73.06 |
| Indicator | WLDN | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 23.16 |
| Support Level | $74.39 | $13.06 |
| Resistance Level | $85.35 | $72.89 |
| Average True Range (ATR) | 3.89 | 0.55 |
| MACD | 1.25 | 1.76 |
| Stochastic Oscillator | 55.52 | 80.32 |
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.